CClinicalTrials.gg
CompletedNCT03630016Updated Jul 23, 2019Results posted

SpO2 Accuracy Comparison of Smart Sock V. 2 SpO2 to Arterial Blood CO-Oximetry

An interventional study of Pulse oximetry with Owlet BabySat v1.0 sensor in Hypoxia, sponsored by Owlet Baby Care, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-23.

Sponsored by Owlet Baby Care, Inc. · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Dec 2017, registered Aug 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
11
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

Pulse oximetry monitoring is considered a standard physiological measurement and is used by clinicians in everyday situations to estimate arterial oxygen saturation. There are two devices used in this investigational study: BabySat v.1.0 and Owlet Baby Care, Inc. Smart SockTM 2 (currently available over-the-counter), with specific emphasis on its pulse oximetry accuracy. The BabySat and Smart SockTM 2 are non-invasive home care devices for use with infants. The purpose of this study was to validate the SpO2 accuracy of BabySat v1.0 and Owlet Smart SockTM 2, OSS v1.1 sensors pulse oximetry, during non-motion conditions over the range of 70-100% SaO2 as compared to arterial blood samples assessed by CO-Oximetry.

Read the detailed description

Pulse oximetry monitoring is considered a standard physiological measurement and is used by clinicians in everyday situations to estimate arterial oxygen saturation. A pulse oximeter is a device that measures the oxygen saturation of arterial blood non-invasively.

The purpose of this study was to evaluate the SpO2 accuracy performance of the Owlet BabySat v1.0 and Smart SockTM 2 pulse oximetry OSS v1.1 sensors during non-motion conditions over the range of 70-100% SaO2 to arterial blood samples assessed by CO-Oximetry for a SpO2 validation.

The goal, in its entirety, was to show the SpO2 accuracy performance for the investigational device Owlet Baby Care, Inc. Smart SockTM V. 2.

It was expected that the Accuracy Root Mean Square (ARMS) performance would meet the required specification of ARMS 3% or lower in non-motion conditions for the range of 70 - 100% SaO2 thereby demonstrating an acceptable SpO2 accuracy performance specification.

No risks or adverse device effects were expected. There were no contraindications for use in the proposed study population.

The study was conducted in accordance to the code of federal regulations for non-significant risk medical device studies and applicable ISO 14155 (2nd edition 2011-02-01), applicable sections of ISO80601-2-61 (1st edition 2011-04- 01), and Pulse Oximeters - Premarket Notifications Submissions [510(k)s] Guidance For Industry and Food and Drug Administration Staff (issued: March 4, 2013)

02

Conditions studied

  • Hypoxia

Browse trials for

03

In context

Hypoxia

1,231 studies on the registry are indexed under Hypoxia; 241 are open to participants now.

This study's enrollment of 11 is below the median of 45 across 853 interventional studies indexed under Hypoxia.

Browse Hypoxia studies →

Lead sponsor

Owlet Baby Care, Inc. is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • 10-15 Adults with a minimum of 3 males and a minimum of 3 females, with the balance, made up of either.
  • Subject must have the ability to understand and provide written informed consent
  • Subject is 18 to 50 years of age
  • At least 2 darkly pigmented subjects or 15% of the subject pool, whichever is larger
  • Subject must be willing and able to comply with study procedures and duration
  • Subject is a non-smoker or who have not smoked within 2 days prior to the study.

Exclusion criteria

Exclusion Criteria:

  • Subject is considered as being morbidly obese (defined as BMI >39.5)
  • Compromised circulation, injury, or physical malformation of fingers, toes, hands, ears or forehead/skull or other sensor sites which would limit the ability to test sites needed for the study
  • Females who are pregnant, who are trying to get pregnant
  • Smoker Subjects who have refrained will be screened for COHb levels
  • Subjects with known heart or cardiovascular conditions
  • Subjects with known clotting disorders
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Active comparator
    Reference CO-Oximetry

    Reference Co-Oximetry

    Diagnostic Test: Pulse oximetry with Owlet BabySat v1.0 sensor

  • Experimental
    Owlet BabySat v1.0

    Owlet BabySat v1.0

    Diagnostic Test: Pulse oximetry with Owlet BabySat v1.0 sensor

  • Experimental
    Owlet Smart Sock V2 v1.1

    Owlet Smart SockTM 2 , OSS v1.1 Sensor and Custom Adult Thumb Sock

    Diagnostic Test: Pulse oximetry with Owlet BabySat v1.0 sensor

Interventions

  • Diagnostic testPulse oximetry with Owlet BabySat v1.0 sensor

    A comparative, single-center, non-randomized study to evaluate the SpO2 accuracy guidelines for pulse oximetry over the range of 70-100% SaO2 under non-motion conditions. Arterial blood sampling measured by functional SaO2 CO-Oximetry, was used as the basis for comparison with Owlet BabySat v1.0 and Owlet Smart Sock 2 sensors

06

What researchers measure

Primary outcomes

  1. It Was Expected That the Accuracy Root Mean Square (ARMS) Between Measured SpO2 of Owlet Smart Sock V2 v1.1 and Reference SpO2 Would Meet the Required Specification of ARMS 3% or Lower in Non-motion Conditions for the Range of 70 - 100%

    The purpose of the study was to evaluate the accuracy of the blood oxygen saturation (SpO2) at rest over the range of 70-100% compared to arterial blood samples assessed by standard methods \[Co-Oximetry\]. A standard pulse oximeter accuracy is evaluated by the Accuracy Root Mean Square (ARMS). The results of accurate performance of the oximetry system require ARMS of 3% or less in non-motion conditions for the range of 70-100% SpO2 per standard.

    Time frame: Acute immediate assessment of the sensor accuracy compared to CO-oximetry

07

Results

Posted Jul 23, 2019

Participant flow

Participant flow — Overall Study
MilestoneOwlet Smart Sock V2 v1.1
Started11
Completed10
Not completed1
Withdrew: Poor sensor placement1

Outcome measures

PrimaryIt Was Expected That the Accuracy Root Mean Square (ARMS) Between Measured SpO2 of Owlet Smart Sock V2 v1.1 and Reference SpO2 Would Meet the Required Specification of ARMS 3% or Lower in Non-motion Conditions for the Range of 70 - 100%

The purpose of the study was to evaluate the accuracy of the blood oxygen saturation (SpO2) at rest over the range of 70-100% compared to arterial blood samples assessed by standard methods \[Co-Oximetry\]. A standard pulse oximeter accuracy is evaluated by the Accuracy Root Mean Square (ARMS). The results of accurate performance of the oximetry system require ARMS of 3% or less in non-motion conditions for the range of 70-100% SpO2 per standard.

Time frame:
Acute immediate assessment of the sensor accuracy compared to CO-oximetry
Reported as:
Number · Percent SpO2
It Was Expected That the Accuracy Root Mean Square (ARMS) Between Measured SpO2 of Owlet Smart Sock V2 v1.1 and Reference SpO2 Would Meet the Required Specification of ARMS 3% or Lower in Non-motion Conditions for the Range of 70 - 100%
Percent SpO2Owlet Smart Sock V2 v1.1
It Was Expected That the Accuracy Root Mean Square (ARMS) Between Measured SpO2 of Owlet Smart Sock V2 v1.1 and Reference SpO2 Would Meet the Required Specification of ARMS 3% or Lower in Non-motion Conditions for the Range of 70 - 100%2.4

Adverse events

Collected over Throughout study duration and a follow-up with each subject will be conducted within 7 days following participation in the study and will be conducted via telephone, text or email.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Owlet Smart Sock V2 v1.10/11 (0%)0/11 (0%)0/11 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Owlet Smart Sock V2 v1.1
<=18 years0
Between 18 and 65 years10
>=65 years0
Age, Continuous
Age, Continuous(years)Owlet Smart Sock V2 v1.1
Mean29.2 ± 7.2
Sex: Female, Male
Sex: Female, Male(Participants)Owlet Smart Sock V2 v1.1
Female4
Male6
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Owlet Smart Sock V2 v1.1
Hispanic or Latino2
Not Hispanic or Latino8
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Owlet Smart Sock V2 v1.1
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American2
White7
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Owlet Smart Sock V2 v1.1
United States10
Weight
Weight(lbs)Owlet Smart Sock V2 v1.1
Mean159.8 ± 25.8
Height
Height(inches)Owlet Smart Sock V2 v1.1
Mean68.1 ± 4.3
08

Study locations

1 site
  • Owlet Baby Care, Inc.
    Lehi, Utah 84043, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Nov 30, 2017

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03630016
Lead sponsor
Owlet Baby Care, Inc.
Collaborators
Clinimark, LLC
Responsible party
Sponsor
First posted
Aug 14, 2018
Start date
Dec 13, 2017
Primary completion
Dec 17, 2017
Completion
Dec 17, 2017
Results posted
Jul 23, 2019
Last update
Jul 23, 2019

Study contacts

Milena Adamian, MD
study director · Owlet Baby Care, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion